Marshall Wace’s TriSalus Life Sciences TLSI Stock Holding History

Marshall Wace’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-795,519	Closed	-$7.9M	–	3425
2022 Q3	$7.9M	Hold	795,519	–	–	0.02%	1062
2022 Q2	$7.83M	Hold	795,519	–	–	0.02%	1045
2022 Q1	$7.79M	Hold	795,519	–	–	0.01%	1052
2021 Q4	$7.86M	Sell	795,519 -33,436	-4%	-$332K	0.01%	1041
2021 Q3	$8.23M	Buy	828,955 +12,869	+2%	+$126K	0.03%	666
2021 Q2	$7.96M	Buy	816,086 +100,000	+14%	+$980K	0.04%	595
2021 Q1	$6.91M	Buy	+716,086	New	+$7.26M	0.03%	647

Other funds holding TLSI

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

DFCM

Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marshall Wace's TLSI Position: Q4 2022 in Review

Marshall Wace sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 795,519 shares — an estimated $7.9M sold.

Marshall Wace first reported a position in TLSI in Q1 2021 and held it in 7 quarters. The position peaked at $8.23M in Q3 2021. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

Marshall Wace reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
Marshall Wace sold 795,519 TriSalus Life Sciences shares in Q4 2022, an estimated $7.9M.
Marshall Wace first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 7 quarters.
Marshall Wace's TriSalus Life Sciences position peaked at $8.23M in Q3 2021.
9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.